(Boursier.com) — Transgene and NEC Corporation announced the signing of a collaboration agreement for the continued clinical evaluation of the individualized neoantigenic cancer vaccine TG4050.
TG4050 is currently in a multicenter Phase I trial as a single agent as an adjuvant treatment for HPV-negative head and neck cancers. Building on the first results obtained, Transgene and NEC are therefore preparing the extension of this randomized Phase I trial into a randomized Phase I/II trial. Its start-up is expected in 2024.
This new phase, which capitalizes on the first signs of efficacy and the induction of lymphocytic immune responses in patients, aims to generate a set of immunological and clinical results that will further demonstrate the potential of TG4050.
Transgene and NEC will present additional immunological and clinical data from the current Phase I trial at a scientific conference in the first half of 2024.
TG4050 comes from Transgene’s “myvac” platform and benefits from NEC’s Artificial Intelligence (AI) technologies for the identification and prediction of the most immunogenic neoantigens.
©2024 Boursier.com